Wall Street Analysts Predict a 25.59% Upside in BioNTech (BNTX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 25.6% in BioNTech (BNTX). While the effectiveness of this highly sought-after metric is questionable, the ...
BioSpace4d
BioNTech Strives to Become Commercial ‘Powerhouse’ While Maintaining Humility
Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she ...
Truist Financial Issues a Buy Rating on BioNTech SE (BNTX)
In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to BioNTech SE (BNTX – Research Report). The ...
Goldman Sachs Sticks to Their Buy Rating for BioNTech SE (BNTX)
In a report released today, Chris Shibutani from Goldman Sachs maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...
The Pharma Letter6d
BioNTech reveals priorities and progress at JPM
German biotech BioNTech is today presenting its 2025 strategic priorities and progress on the company’s pipeline of mRNA ...
BioNTech SE: BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches BioNTech aims to develop BNT327/PM8002 as a next-genera ...